Article Details
Retrieved on: 2024-02-12 19:04:47
Tags for this article:
Click the tags to see associated articles and topics
Summary
The FDA is evaluating Abbott's Triclip device for treating severe tricuspid regurgitation, focusing on its safety and efficacy based on clinical trial outcomes, with insights from J.P. Morgan analysts suggesting potential approval. The case highlights advancements and challenges in the MedTech industry's cardiac sector.
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here